Abstract
Fibroblast growth factor 23 (FGF23) is a phosphotropic hormone mainly produced by osteocytes. FGF23 binds to Klotho-FGF receptor complex and reduces serum phosphate by suppressing intestinal phosphate absorption and proximal tubular phosphate reabsorption. Excessive and deficient actions of FGF23 result in hypophosphatemic and hyperphosphatemic diseases, respectively. FGF23 level can be high in patients with chronic kidney disease (CKD). Epidemiological studies reported the associations between high FGF23 and various adverse events especially in patients with CKD. There are also several reports of Klotho-independent FGF23 actions. Several inhibitory measures of FGF23 activity have been considered as new treatments for FGF23-reltaed hypophosphatemic diseases.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
